Ultimate Guide to CRAMS or CDMO with various Companies to Track

Reading Time: 3 minutes


Ultimate Guide to CRAMS or CDMO  with various companies to track

What are CRAMS?

CRAMS is defined as the process of
outsourcing research services/ product manufacturing activities to
organizations which can provide the service at a low cost. CRAMS basically
consists of the following two activities: contract research and contract
manufacturing. CRAMS is mainly used in the Pharmaceutical and Biotechnology
sectors that require extensive R&D and large-scale manufacturing
facilities. It is expected that the demand for contract research and contract
manufacturing is expected to increase in India in the future.

Roadmap Ahead

Investments in the global pharmaceuticals
sector to increase to over $1,400 billion over the next three years, driven by
a number of new medicines. With healthy R&D spending going forward, the
Contract Research and Manufacturing (CRAMS) segment offers growth opportunities
to Indian companies.

Rising demand for generic formulations,
increased investments in pharmaceutical Research & Development and advanced
manufacturing technologies by contract development and manufacturing
organization (CDMO’s) are key factors contributing to the high CAGR of
Pharmaceutical Contract Manufacturing market during the forecast period.

Market Size – USD 82430.9 Million in 2018,
Market Growth – CAGR of 7.2 %, Market Trends – Increasing outsourcing of
clinical trials, increasing CDMO’s manufacturing footprint in Asia. The
pharmaceutical industry uses outsourcing services from providers in the form of
contract research organizations (CROs) and contract manufacturing organizations
(CMOs). Comprehensive single-source provider from drug development through
commercial manufacture has emerged in recent years.

It is known as contract research and
manufacturing services (CRAMS), or contract development and manufacturing
organizations (CDMO). Pharmaceutical Contract Manufacturing organizations are a
response to the competitive international nature of the pharmaceutical market
as well as the increasing demand for outsourced services.

Let’s Discuss in Nutshell
Few Companies that I have covered in detail previously in my blogs.

in 1988, Hikal is predominantly a B2B player that provides intermediates and
active ingredients to global pharmaceutical, animal health, crop protection and
specialty chemical companies

For FY20, pharma and crop protection
accounted for 59% and 41%, respectively, of operating revenues.
Also Read on FinMedium:  Instant Redemption Liquid Funds (2020) Rs 50,000 per day: Is it Good?

The pharma
business is currently divided almost equally between generic active pharma
ingredients (APIs) and contract development and manufacturing organisation
(CDMO) businesses.

health business accounts for 20-25% of CDMO business. In crop protection, 70%
of revenues are derived from CDMO with the remaining from proprietary products,
specialty chemicals and specialty biocides. Leading Sustainable Technology
driven company serving the Crop Protection & Pharmaceutical Industries.

Company’s Crop Protection CDMO segment has 2-3
products in the pipeline currently
. These are all early stage products.
Overall, product pipeline is healthy.

Growth Trend over the Years

Laurus Labs
–The Complete Turnaround Story

Laurus Labs is a leading R&D driven
pharmaceuticals company established in 2005 with its headquarters in Hyderabad.
It is among the leaders in the manufacturing of Active Pharmaceutical
Ingredients (APIs) for Antiretroviral (ARV) and Hepatitis C (Hep-C)
formulations. Other major API segments include therapeutic areas such as
Oncology, Cardiovascular, and Anti-Diabetes.

From a one-product company in 2010
to an Active Pharmaceutical Ingredients (APIs) company thereafter, company has
now emerged as one of India’s leading manufacturers of generics APIs for
various complex therapies.

Comparison FY19 v/s FY20

Also Read on FinMedium:  Muthoot Finance Ltd- Analysis

Source link

Disclaimer: The opinions expressed in this publication are those of the authors. They do not purport to reflect the opinions or views of the FinMedium or its members. The presentation of material therein does not imply the expression of any opinion whatsoever on the part of the FinMedium concerning the legal status of any company, country, area, or territory or of its authorities. For more info. please read our ToU & Privacy Policy here. If you have any concerns regarding this post, please reach out to our grievance officer Ghanisht Nagpal and drop a mail to editor@finmedium.com

Every Wednesday and Saturday, we send Info-Graphic and FinMedium Weekly Digest newsletters to our 25000+ Subscribers.

Join Them Now!

Shuchi Nahar

Shuchi Nahar

Shuchi is NISM Certified Equity Research Analyst, CFA - Level 1, a student of Law and Finance, and an aspiring CS.
Please Share Now :)